We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Medical News & Perspectives |

Studies Shed Light on Risks and Trends in Pediatric Antipsychotic Prescribing

Bridget M. Kuehn
JAMA. 2010;303(19):1901-1903. doi:10.1001/jama.2010.596.
Text Size: A A A
Published online


Studies continue to document worrisome trends in pediatric antipsychotic prescribing, as evidence builds about the risks of substantial weight gain and emergent metabolic problems in children and adolescents who take these drugs. Moreover, the studies suggest physicians may be missing opportunities to minimize the drugs' risks.

Until recently, only two atypical antipsychotic drugs were approved by the US Food and Drug Administration (FDA) for use in children and adolescents. Risperidone was approved for use in patients aged 13 to 17 years with schizophrenia, patients aged 10 to 17 years for manic or mixed episodes associated with bipolar disorder, and patients aged 5 to 16 years for irritability associated with autism. Aripiprazole was approved to treat schizophrenia in individuals aged 13 to 17 years, and for use alone or as an adjunct to lithium or valproate in individuals aged 10 to 17 years with bipolar mania.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption

Graphic Jump LocationImage not available.

Physicians must carefully weigh both the benefits of using antipsychotic drugs to treat children with serious psychiatric disorders and the serious metabolic risks associated with the drugs.



Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

3 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections

Care at the Close of Life: Evidence and Experience
Pharmacologic Management

Care at the Close of Life: Evidence and Experience
Typical Antipsychotic Medications